Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck and : & Co. Raises Quarterly Dividend by 10.9% to 61 Cents

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/19/2019 | 01:07pm EST

By Colin Kellaher

Merck & Co. (MRK) on Tuesday said its board raised the quarterly dividend by 10.9% to 61 cents from 55 cents.

The new payout, equal to $2.44 a year, represents an annual yield of about 2.9% based on Monday's closing price of $84.13, up from 2.62%.

The Kenilworth, N.J., drug maker said the increased dividend is payable Jan. 8 to shareholders of record Dec. 16.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
HUDSON'S BAY COMPANY 0.27% 9.155 Delayed Quote.25.24%
MERCK AND COMPANY -0.26% 88.63 Delayed Quote.16.28%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
10:59aMERCK AND : to Buy ArQule for $2.7 Billion -- Update
DJ
10:21aOsram acquired by AMS, Tesco sells supermarkets in Asia, and other companies’..
09:16aDAVID KLEIN : Top Company News of the Day
DJ
08:13aMERCK AND : LYNPARZA (olaparib) Approved in China as a First-Line Maintenance Th..
AQ
07:12aMERCK AND : to Buy ArQule for $2.7 Billion, or $20/Share
DJ
06:46aMERCK : to Acquire ArQule, Advancing Leadership in Oncology
BU
12/06MERCK AND : AstraZeneca - Lynparza approved in China as a 1st-line maintenance t..
AQ
12/05MERCK AND : LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance T..
BU
12/05ASTRAZENECA : Lynparza approved in China for 1L BRCAm ovarian
AQ
12/04MERCK AND : Cote d' Ivoire and Liberia both Launch National Immunisation Program..
AQ
More news
Financials (USD)
Sales 2019 46 686 M
EBIT 2019 16 304 M
Net income 2019 10 013 M
Debt 2019 18 828 M
Yield 2019 2,51%
P/E ratio 2019 23,1x
P/E ratio 2020 18,5x
EV / Sales2019 5,25x
EV / Sales2020 4,90x
Capitalization 226 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Average target price 98,12  $
Last Close Price 88,85  $
Spread / Highest target 18,2%
Spread / Average Target 10,4%
Spread / Lowest Target 1,29%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY16.28%226 211
JOHNSON & JOHNSON8.78%369 462
ROCHE HOLDING AG25.45%263 079
PFIZER-12.28%211 902
NOVARTIS22.87%208 547
BRISTOL-MYERS SQUIBB COMPANY15.33%140 534